Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of β-thromboglobulin, platelet factor 4, thromboxane B2, 6-keto-prostaglandin F1α and heparin

• Published in: Thrombosis research Vol. 32; no. 4; pp. 393 - 408
• Main Authors: DITTER, H, HEINRICH, D, MATTHIAS, F. R, SELLMAN-RICHTER, R, WAGNER, W. L, HEHRLEIN, F. W
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Science 15.11.1983
• Subjects: 6-Ketoprostaglandin F1 alpha - blood; Beta-Globulins - analysis; beta-Thromboglobulin - analysis; Biological and medical sciences; Blood Platelets - metabolism; Blood. Blood coagulation. Reticuloendothelial system; Cardiopulmonary Bypass; Double-Blind Method; Epoprostenol - therapeutic use; Heparin - blood; Humans; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Platelet Count; Platelet Factor 4 - analysis; Random Allocation; Thromboxane B2 - blood; Thromboxanes - blood; Human; Prostaglandin I2; Cardiovascular disease; Cardiopulmonary; Thromboxane B2; Blood plasma; Cardiopulmonary bypass; Platelet factor 4; Chemotherapy; Treatment; Bypass; Surgery; Platelet function; Double blind study; Ratio; Heparin
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/0049-3848(83)90092-0

A randomized double-blind study was carried out on 40 male patients requiring aorto-coronary bypass surgery. 20 patients received a constant dose of 8 ng kg-1 min-1 of prostacyclin (PGI2), beginning two minutes before extracorporeal circulation (ECC) and ending together with ECC. Compared to the placebo-treated patient group (n = 20), PGI2-treatment significantly reduced the ECC-induced release of platelet alpha-granule proteins, beta-thromboglobulin (1178 ng/ml vs. 1926 ng/ml) and platelet factor 4 (837 ng/ml vs. 1245 ng/ml) into plasma (mean of max. values). Furthermore the decrease of platelet counts during ECC was less pronounced in PGI2-treated patients. Application of PGI2 had no effect on the increase in thromboxane B2 (TxB2) plasma levels, which amounted to 0.6 ng/ml at the end of ECC. PGI2-treatment resulted in significantly elevated plasma concentrations of 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) (2.1 ng/ml) throughout the infusion off prostacyclin. 6-keto-PGF1 alpha plasma levels increased up to 1.2 ng/ml in the control group patients, indicating a stimulation of endogenous PGI2 formation during ECC.